Key result
In a cohort of 160 patients with a known atrial septal defect or patent foramen ovale undergoing primary hip or knee arthroplasty, there were no intraoperative or postoperative embolic events within 90 days.
Why the study?
Congenital heart defects such as atrial septal defects and patent foramen ovale may increase the risk of embolic events in total hip or knee arthroplasty.
Cohort (n=160)
No
In patients with known ASD or PFO undergoing total joint arthroplasty with multimodal thromboprophylaxis, the risk of 90-day embolic events is extremely low.
Background: Congenital heart defects, such as atrial septal defects (ASDs) and patent foramen ovale (PFO), may increase the risk of embolic events in total hip or knee arthroplasty (THA/TKA). The objective of this study was to determine the 90-day incidence of intraoperative and postoperative embolic events and all other complications in patients with a known ASD/PFO who underwent primary hip and knee arthroplasty. Methods: (SD 7.2). The mean follow-up period was 19 months (SD 16). Forty-three percent of patients were on anticoagulation preoperatively. All patients received postoperative thromboprophylaxis (48% aspirin, 31% direct oral anticoagulants, 18% warfarin, 3% enoxaparin). Results: There were no embolic events identified. Fourteen patients (7%) developed complications within 90 days. Three had bleeding complications, and 8 had other nonoperative complications, which were all managed conservatively and had uneventful recoveries. Additionally, 3 patients had complications requiring reoperations: 2 for periprosthetic fractures (1 THA, 1 TKA) and 1 for a periprosthetic infection (TKA). Conclusions: In this cohort of patients with a known ASD/PFO undergoing THAs and TKAs, there were no cases of embolic events. However, it would be advisable to have a thorough cardiology evaluation to assess potential risks and benefits of defect repair prior to total joint arthroplasty and to reduce the risk of paradoxical embolic events and the necessity of potent anticoagulation. Level of evidence: Prognostic Level IV.
No takes yet. Share an insight, caveat, or question.
Bido et al. (2022) conducted a cohort in Atrial septal defects (ASD) or patent foramen ovale (PFO) requiring primary hip or knee arthroplasty (n=160). Primary hip or knee arthroplasty in patients with ASD/PFO was evaluated on 90-day incidence of intraoperative and postoperative embolic events. In a cohort of 160 patients with a known atrial septal defect or patent foramen ovale undergoing primary hip or knee arthroplasty, there were no intraoperative or postoperative embolic events within 90 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: